Cancer drugs · Clin Cancer Res · 2021
Summary: 11 of the 34 patients on both drugs responded. Its own table: 8.
Of the 34 patients on both drugs, the number who responded
The paper says
In the rising-dose stage of a trial of a new cancer drug, MK-4830, 84 patients took part: 50 got it alone, 34 together with an existing immune drug, pembrolizumab. The paper’s summary says 11 of those 34 responded: their tumors shrank by at least 30%.
Its own data show
Its own table counts 8 of the 34 as responding (24%), each with shrinkage that held on a second scan; one more whose shrinkage was not confirmed makes 9. The 11 is the paper’s count for all 84 patients: those 9, plus 1 on MK-4830 alone and 1 who later switched to both drugs.
A response rate is one group’s responders divided by that same group’s size. No group on both drugs in the paper has 11 responders. As a share of the 34, 11 makes the drug pair look better: about 32% instead of the table’s 24%. It is the summary’s only result on whether the treatment works.